Diabetes drug semaglutide takes on dieting in fatty liver showdown

NCT ID NCT07272343

Recruiting now Disease control Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares weekly semaglutide injections to a calorie-restricted diet in 100 adults with type 2 diabetes and fatty liver disease. Over 12 weeks, researchers will measure changes in blood sugar, weight, inflammation, and liver fat. The goal is to see which approach works better and understand the underlying molecular mechanisms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this could show that semaglutide is more effective than dieting alone for controlling blood sugar and reducing liver fat in people with type 2 diabetes and fatty liver disease.
What could go wrong: This is a small, early-phase (Phase 4) study with only 100 participants over 12 weeks. Results may not apply to everyone, and semaglutide can cause side effects like nausea or vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CALORIC RESTRICTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CALORIC RESTRICTION SEMAGLUTIDE TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Minde road No.1
RECRUITING

Jiangxi, Nanchang, 330000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.